论文部分内容阅读
目的 :观察布地奈德干粉吸入剂 (商品名 :普米克都保 )吸入治疗支气管哮喘的疗效及起效时间。方法 :将 38例哮喘缓解期患者随机分为 2组 :试验组 18例 ,吸入普米克都保 4 0 0 μg ,bid ;对照组 2 0例 ,口服茶碱控释胶囊 (商品名 :时尔平 ) 0 .2 g ,bid ,2组均按需使用沙丁胺醇气雾剂 (商品名 :喘乐宁 ) ,疗程均为 8周 ,治疗前后观察哮喘症状 ,测定肺功能 ,对普米克都保组其中 8例进行每日晨晚PEFR监测。结果 :试验组治疗 2周后 ,其用力肺活量 (FVC) ,1s用力呼气量 (FEV1 ) ,最大呼气流量 (PEFR) ,用力呼气中期流量 (FEF2 5～ 75)和 5 0 %肺活量 (V50 )均有明显改善 (P <0 .0 1) ,随治疗时间延长 ,肺功能进一步改善 ,对照组上述指标无明显变化。吸入普米克都保治疗 4d ,每日晨晚PEFR值即有明显升高 (P <0 .0 5 )。结论 :普米克都保能及时有效地治疗支气管哮喘。
OBJECTIVE: To observe the efficacy and duration of inhalation of budesonide dry powder inhaler (brand name: Pulmicort) for the treatment of bronchial asthma. Methods: Thirty-eight asthma remission patients were randomly divided into two groups: 18 in the test group, 400 μg of bidimycin in the inhalation group, 20 in the control group and oral theophylline controlled release capsules (trade name: Flat) 0.2 g, bid, 2 groups were used on demand salbutamol aerosol (trade name: Salbutamol), treatment were 8 weeks, before and after treatment to observe the symptoms of asthma, lung function was measured, Eight of them performed daily morning PEFR monitoring. Results: After 2 weeks of treatment, the forced vital capacity (FVC), forced expiratory volume (FEV1), maximum expiratory flow (PEFR), forced expiratory flow (FEF2 5 ~ 75) and 50% V50) were significantly improved (P <0.01), with the extension of treatment time, pulmonary function further improved in the control group no significant change in the above indicators. Pfeiffer treatment inhalation 4d, daily morning PEFR value was significantly increased (P <0. 05). Conclusions: Pulmicort are able to treat bronchial asthma promptly and effectively.